Alto Ingredients Leads 3 US Penny Stocks To Consider

As the U.S. stock market experiences a mixed performance with major indices like the Dow Jones and Nasdaq reaching new highs, investors continue to explore diverse opportunities across various sectors. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.81715	$5.81M	★★★★★★
Inter & Co (NasdaqGS:INTR)	$4.56	$2.03B	★★★★☆☆
QuantaSing Group (NasdaqGM:QSG)	$3.08	$136.98M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.2421	$8.86M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.58	$52.47M	★★★★★★
Zynerba Pharmaceuticals (NasdaqCM:ZYNE)	$1.30	$65.6M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.9597	$84.8M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.76	$413.23M	★★★★☆☆
Smith Micro Software (NasdaqCM:SMSI)	$0.825	$15.25M	★★★★★☆

Click here to see the full list of 709 stocks from our US Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Alto Ingredients (NasdaqCM:ALTO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Alto Ingredients, Inc. is involved in the production, distribution, and marketing of specialty alcohols, renewable fuel, and essential ingredients in the United States with a market cap of approximately $111.14 million.

Operations: The company's revenue is primarily derived from Pekin Campus Production ($606.10 million), Marketing and Distribution ($237.13 million), and Western Production ($159.33 million).

Market Cap: $111.14M

Alto Ingredients, Inc. has faced challenges with declining sales and increased net losses over the past year, yet it remains focused on strategic initiatives to enhance operational efficiency and environmental sustainability. The company reported third-quarter sales of US$251.81 million, down from US$318.13 million the previous year, with a net loss of US$2.44 million. Despite these setbacks, Alto's financial position is supported by short-term assets exceeding liabilities and a satisfactory debt level with a net debt to equity ratio of 18.9%. Recent efforts include entering a CO2 sequestration agreement at its Pekin campus and optimizing production at its Magic Valley facility for higher-margin products like high-protein feed and corn oil.

• Navigate through the intricacies of Alto Ingredients with our comprehensive balance sheet health report here.
• Gain insights into Alto Ingredients' outlook and expected performance with our report on the company's earnings estimates.

Applied Energetics (OTCPK:AERG)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Applied Energetics, Inc. provides advanced optical and ultrashort pulse directed energy solutions for defense, national security, industrial, biomedical, and scientific sectors worldwide with a market cap of $157.68 million.

Operations: The company's revenue is primarily derived from its Aerospace & Defense segment, totaling $2.53 million.

Market Cap: $157.68M

Applied Energetics, Inc. is navigating financial challenges with a net loss of US$2.37 million in the third quarter of 2024, despite modest sales growth to US$0.75 million from the previous year. The company remains unprofitable and has less than a year of cash runway based on current free cash flow trends. However, recent strategic leadership changes could signal a shift in direction; Chris Donaghey, an experienced defense industry executive, now leads as President and CEO following Dr. Gregory Quarles' transition to focus on government relations and strategic partnerships for future growth opportunities within defense sectors.

• Get an in-depth perspective on Applied Energetics' performance by reading our balance sheet health report here.
• Learn about Applied Energetics' historical performance here.

Investview (OTCPK:INVU)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Investview, Inc., operates through its subsidiaries to offer financial education, digital assets, and related technology services for individuals, with a market cap of $29.19 million.

Operations: The company generates revenue of $58.45 million from its online financial information provider segment.

Market Cap: $29.19M

Investview, Inc. has shown resilience in the penny stock arena with a market cap of US$29.19 million and revenue of US$58.45 million from its financial services segment. Despite a recent net loss of US$0.81 million for Q3 2024, the company maintains profitability over the past year and has improved its financial position by reducing debt levels and covering interest payments comfortably with EBIT (4.5x coverage). The firm also announced a significant share buyback program, potentially enhancing shareholder value by repurchasing up to 121 million shares at a discount, indicating confidence in its future prospects despite current volatility challenges.

• Take a closer look at Investview's potential here in our financial health report.
• Evaluate Investview's historical performance by accessing our past performance report.

Turning Ideas Into Actions

• Dive into all 709 of the US Penny Stocks we have identified here.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com